GAITHERSBURG, Md., Nov. 15 /PRNewswire-FirstCall/ -- MedImmune, Inc.
(Nasdaq: MEDI) announced today that it has appointed Francois Lebel, M.D. as
vice president, medical affairs, reporting to Edward M. Connor, M.D.,
executive vice president and chief medical officer, effective immediately.
"Continuing to expand our depth of scientific and medical expertise, I am
pleased to welcome Francois to our team of biotechnology executives dedicated
to the corporate mission of advancing science for better health," said Dr.
As vice president, medical affairs, Dr. Lebel oversees MedImmune's medical
activities relating to our marketed products, including clinical trials and
medical information. Dr. Lebel has more than 15 years of drug development
experience, having played a key role in four new drug applications to the U.S.
Food & Drug Administration. In addition, he has conducted several late-stage
virology and oncology studies, including using patient registries to explore
new indications. He gained extensive international experience from the launch
of a number of products in more than 40 countries. Dr. Lebel has a strong
record of accomplishments in a variety of increasingly responsible medical,
regulatory and quality assurance positions held at Parke-Davis (Warner-
Lambert), Galagen, Inc., and Burroughs Wellcome, Inc. In 2000, he joined
PathoGenesis Corp., where he facilitated the company's integration with
Chiron, becoming Chiron-Seattle general manager. Most recently, he served as
divisional vice president and head, global medical affairs at Chiron
headquarters in Emeryville, California. Dr. Lebel holds bachelor's and
medical degrees from the University of Ottawa and trained in Microbiology and
Infectious Diseases at McGill University and Harvard Medical School.
About MedImmune, Inc.
MedImmune strives to provide better medicines to patients, new medical
options for physicians, rewarding careers to employees, and increased value to
shareholders. Dedicated to advancing science and medicine to help people live
better lives, the company is focused on the areas of infectious diseases,
cancer and inflammatory diseases. With approximately 1,900 employees
worldwide, MedImmune is headquartered in Maryland. For more information,
visit the company's website at http://www.medimmune.com.
This announcement may contain, in addition to historical information,
certain forward-looking statements that involve risks and uncertainties. Such
statements reflect management's current views and are based on certain
assumptions. Actual results could differ materially from those currently
anticipated as a result of a number of factors, including risks and
uncertainties discussed in MedImmune's filings with the U.S. Securities and
Exchange Commission. The company is developing several products for potential
future marketing. There can be no assurance that such development efforts
will succeed, that such products will receive required regulatory clearance or
that, even if such regulatory clearance were received, such products would
ultimately achieve commercial success.
SOURCE MedImmune, Inc.
/CONTACT: Media: Jamie Lacey, +1-301-398-4035, or Investors: Peter Vozzo,
+1-301-398-4358, or John Filler, +1-301-398-4086, all of MedImmune, Inc./
/Web site: http://www.medimmune.com/
CO: MedImmune, Inc.
IN: HEA MTC BIO
-- DCM062 --
4149 11/15/2004 14:45 EST http://www.prnewswire.com